{"log_id": 4858474065887311107, "direction": 0, "words_result_num": 39, "words_result": [{"probability": {"variance": 0.001653, "average": 0.981238, "min": 0.823167}, "location": {"width": 1069, "top": 283, "height": 54, "left": 301}, "words": "目前尚无本品对肝肾功能不全患者影响的相关数据,建议肝肾功能不全患者应根据临床情"}, {"probability": {"variance": 0.006433, "average": 0.976025, "min": 0.553211}, "location": {"width": 886, "top": 324, "height": 50, "left": 246}, "words": "况和实验室检查指标在医师指导下慎用本品,重度肝肾功能不全患者禁用"}, {"probability": {"variance": 6.8e-05, "average": 0.993725, "min": 0.979519}, "location": {"width": 114, "top": 370, "height": 31, "left": 299}, "words": "剂量调整"}, {"probability": {"variance": 0.012841, "average": 0.964469, "min": 0.355977}, "location": {"width": 1076, "top": 408, "height": 50, "left": 294}, "words": "在本品使用过程中应密切监测不良反应,并根据需要进行调整以使患者能够受治疗阿帕替尼"}, {"probability": {"variance": 0.011948, "average": 0.964735, "min": 0.496444}, "location": {"width": 1126, "top": 450, "height": 50, "left": 242}, "words": "所致的不良反应可通过对症治疗、停药和调整尔量等方式处理临木研究中剂量调整多发生在第2.3个"}, {"probability": {"variance": 0.031245, "average": 0.930811, "min": 0.403127}, "location": {"width": 242, "top": 491, "height": 34, "left": 239}, "words": "周期28天为一周期"}, {"probability": {"variance": 0.002503, "average": 0.98624, "min": 0.681988}, "location": {"width": 1076, "top": 527, "height": 54, "left": 292}, "words": "当患者出现3/4级血液学或非血液学不良反应时,建议暂停用药(不超过2周)直至症状"}, {"probability": {"variance": 0.006119, "average": 0.965336, "min": 0.648746}, "location": {"width": 1126, "top": 571, "height": 50, "left": 239}, "words": "缓解或消失,随后继续按原剂量服用;若2周后不良反应仍未缓解,建议在医师指导下调整剂"}, {"probability": {"variance": 0.000508, "average": 0.991, "min": 0.906415}, "location": {"width": 1123, "top": 612, "height": 54, "left": 242}, "words": "量:①第一次调整剂量:750mg,每日一次;②第二次调整剂量:500mg,每日一次(关于剂"}, {"probability": {"variance": 0.004038, "average": 0.979872, "min": 0.645305}, "location": {"width": 1110, "top": 653, "height": 50, "left": 239}, "words": "量调整方法请参考下面表1及后续的【注意事项】)。如需要第三次调整剂量r永久停药"}, {"probability": {"variance": 0.010444, "average": 0.946599, "min": 0.609983}, "location": {"width": 475, "top": 699, "height": 34, "left": 589}, "words": "表1.阿帕替尼治疗晚期胃癌的剂量调整原财"}, {"probability": {"variance": 0.02637, "average": 0.922512, "min": 0.468717}, "location": {"width": 242, "top": 740, "height": 59, "left": 265}, "words": "不良反应分类NcI"}, {"probability": {"variance": 0.016046, "average": 0.872636, "min": 0.745963}, "location": {"width": 52, "top": 788, "height": 29, "left": 452}, "words": "分级"}, {"probability": {"variance": 0.00248, "average": 0.964366, "min": 0.863404}, "location": {"width": 169, "top": 772, "height": 29, "left": 847}, "words": "剂爱调整的规定"}, {"probability": {"variance": 0.011709, "average": 0.953141, "min": 0.395815}, "location": {"width": 1089, "top": 833, "height": 91, "left": 251}, "words": "血液学不良反应暂停用药,待不良反应恢复到2级,以原剂量继续用药。如再次出现3紱或"}, {"probability": {"variance": 0.004036, "average": 0.971573, "min": 0.726087}, "location": {"width": 459, "top": 881, "height": 36, "left": 532}, "words": "以上不良反应,则下调一个剂量后继续用药"}, {"probability": {"variance": 0.023719, "average": 0.918235, "min": 0.464077}, "location": {"width": 728, "top": 932, "height": 45, "left": 466}, "words": "级暂停用药,将不良反应恢复到<2级:下调一个剂量后继续用药"}, {"probability": {"variance": 0.013933, "average": 0.949691, "min": 0.420344}, "location": {"width": 808, "top": 986, "height": 36, "left": 527}, "words": "暂停用药,待不反应恢复到≤1级,以原剂量维续用药;如再次出现3级或"}, {"probability": {"variance": 0.000116, "average": 0.993046, "min": 0.965205}, "location": {"width": 242, "top": 1009, "height": 36, "left": 251}, "words": "非血液学不良反3级"}, {"probability": {"variance": 0.010898, "average": 0.969985, "min": 0.530225}, "location": {"width": 459, "top": 1032, "height": 36, "left": 530}, "words": "以上不良反应,则下调一个剂量后继续用药"}, {"probability": {"variance": 0, "average": 0.996756, "min": 0.996756}, "location": {"width": 27, "top": 1062, "height": 27, "left": 251}, "words": "应"}, {"probability": {"variance": 0.012926, "average": 0.939177, "min": 0.494243}, "location": {"width": 728, "top": 1087, "height": 38, "left": 463}, "words": "级暂停用药,特不良反应恢复到≤级,下调一个剂量后继续用药"}, {"probability": {"variance": 0.018918, "average": 0.943766, "min": 0.4441}, "location": {"width": 772, "top": 1130, "height": 38, "left": 283}, "words": "注:以上采用美国国家癌症研究所指定的常见药物毒性反应分级标准〔N"}, {"probability": {"variance": 0.025752, "average": 0.925424, "min": 0.483659}, "location": {"width": 164, "top": 1142, "height": 29, "left": 1149}, "words": "E4.0)进行评价"}, {"probability": {"variance": 0.002637, "average": 0.979035, "min": 0.70879}, "location": {"width": 1069, "top": 1167, "height": 50, "left": 290}, "words": "对于出现胃肠道穿孔、需要临床处理的伤口裂开、痿、重度出血、肾病综合征或高血压危"}, {"probability": {"variance": 0.010046, "average": 0.965447, "min": 0.522829}, "location": {"width": 1121, "top": 1206, "height": 50, "left": 237}, "words": "象的患者,应永久性地停用本品。尚需进一步确诊的中到重度蛋白尿临床尚未控制的重度高"}, {"probability": {"variance": 0.029706, "average": 0.910481, "min": 0.358175}, "location": {"width": 1039, "top": 1247, "height": 47, "left": 237}, "words": "血压患者,应暂时停止使用本品择期手术之前,应缓本品使用(【注意事项"}, {"probability": {"variance": 2e-06, "average": 0.998688, "min": 0.996064}, "location": {"width": 153, "top": 1290, "height": 29, "left": 244}, "words": "【不良反应"}, {"probability": {"variance": 0.008283, "average": 0.972358, "min": 0.573057}, "location": {"width": 1071, "top": 1334, "height": 47, "left": 287}, "words": "临床试验资料为确定药物可能引起的不良事件及其近似发生率提供了一定的依据。由于临"}, {"probability": {"variance": 0.001192, "average": 0.986678, "min": 0.817789}, "location": {"width": 1123, "top": 1379, "height": 47, "left": 233}, "words": "床试验的条件变化大,试验中观察到的一个药物不良事件的发生率不能直接与另一个药物的临"}, {"probability": {"variance": 0.000503, "average": 0.990483, "min": 0.879345}, "location": {"width": 943, "top": 1425, "height": 45, "left": 233}, "words": "床试验观察到的不良事件发生率相比较,也可能不能反映临床中的实际发生率"}, {"probability": {"variance": 0.000867, "average": 0.985348, "min": 0.860465}, "location": {"width": 1055, "top": 1473, "height": 45, "left": 287}, "words": "有关甲磺酸阿帕替尼应用于晚期胃癌的不良反应信息主要来自一项Ⅲ期、多中心、随机"}, {"probability": {"variance": 0.010578, "average": 0.959237, "min": 0.502766}, "location": {"width": 1123, "top": 1516, "height": 47, "left": 233}, "words": "安慰剂对照临床试验(n=267)受试者均为二线化疗失败的晚期胃癌患者,试验中排除了ECOG"}, {"probability": {"variance": 0.005133, "average": 0.97549, "min": 0.630869}, "location": {"width": 1098, "top": 1564, "height": 45, "left": 258}, "words": "东部肿瘤协作组织)体力状态评分为2分及以上患者、有胃道出血倾向的患者、药物不可"}, {"probability": {"variance": 0.011607, "average": 0.944565, "min": 0.46472}, "location": {"width": 1096, "top": 1610, "height": 41, "left": 233}, "words": "控制的高血压思者、凝血功能异常患者、尿蛋白阳性患者、胆红素≥1.25倍正常值上限的患者"}, {"probability": {"variance": 0.017101, "average": 0.954193, "min": 0.382159}, "location": {"width": 1137, "top": 1654, "height": 47, "left": 226}, "words": "4周内进行过大手术伤口未愈合的患者。176例者服用本品850mgqd治疗。72%的受试者接"}, {"probability": {"variance": 0.004417, "average": 0.981326, "min": 0.601287}, "location": {"width": 1119, "top": 1699, "height": 47, "left": 228}, "words": "受了2个周期或以上的治疗(28天为一个周期)。试验组和安慰剂组不良反应(根据美国国"}, {"probability": {"variance": 0.00744, "average": 0.962135, "min": 0.606191}, "location": {"width": 1105, "top": 1745, "height": 50, "left": 228}, "words": "家癌症研究所通用不良反应分级标准 nci-ctc AE30判断)发生率分别为9205%和71.43%"}, {"probability": {"variance": 0.003699, "average": 0.977274, "min": 0.63807}, "location": {"width": 1121, "top": 1795, "height": 41, "left": 233}, "words": "34级不良反应的发生率分别为51.70%和24.18%。常见不良反应(发生率≥5%)中,试验组"}], "language": 3}